SCHEMBL4129059

SCHEMBL4129059

Cc1[nH]c(/C=C2\C(=O)Nc3c(Nc4cccc(NC(=O)c5ccccc5)c4)cccc32)c(C)c1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 10/20 0.57
KDR P35968 6/20 0.57
FLT4 P35916 5/20 0.57
KIT P10721 2/20 0.57
AURKB Q96GD4 6/20 0.53
NTRK1 P04629 2/20 0.52
ALK Q9UM73 2/20 0.47
PDGFRB P09619 3/20 0.47
AURKA O14965 1/20 0.47
MET P08581 1/20 0.47
AURKC Q9UQB9 1/20 0.47
CSF1R P07333 1/20 0.44
FGFR1 P11362 2/20 0.44
PRKAA2 P54646 1/20 0.44
PRKAA1 Q13131 1/20 0.44
TLK2 Q86UE8 1/20 0.43
ABL1 P00519 1/20 0.42
RET P07949 1/20 0.42
NTRK2 Q16620 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4000250 1.00 FLT3 (0.57) FLT3KDRFLT4KITAURKB
SCHEMBL4138549 0.91 FLT3 (0.55) FLT3KDRFLT4KITAURKB
SCHEMBL3995571 0.91 FLT3 (0.55) FLT3KDRFLT4KITAURKB
SCHEMBL10091906 0.87 KDR (0.64) FLT3KDRFLT4KITAURKB
SCHEMBL396428 0.87 KDR (0.64) FLT3KDRFLT4KITAURKB
SCHEMBL394470 0.86 KDR (0.57) FLT3KDRFLT4KITAURKB
SCHEMBL10091907 0.86 KDR (0.57) FLT3KDRFLT4KITAURKB
SCHEMBL4128689 0.86 RET (0.55) FLT3KDRFLT4KITAURKB
SCHEMBL4128697 0.86 RET (0.55) FLT3KDRFLT4KITAURKB
SCHEMBL3998573 0.85 FLT3 (0.76) FLT3KDRFLT4KITAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814545-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-06-10 EP claimed
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-11 US claimed
EP-1814545-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2007-08-08 EP claimed
WO-2006052936-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-18 WO claimed
EP-1814545-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-06-10 EP disclosed
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-11 US disclosed
EP-1814545-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2007-08-08 EP disclosed
WO-2006052936-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221192-A1 Compounds and Compositions as Protein Kinase Inhibitors BMX, FRK, PTK2B FLT3 93/4885KDR 204/4885FLT4 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.